Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2011 (2011), Article ID 382431, 7 pages
http://dx.doi.org/10.1155/2011/382431
Review Article

Biomarkers in Overactive Bladder: A New Objective and Noninvasive Tool?

1Department of Urology, Hospital de S. João, 4200-319 Porto, Portugal
2Faculty of Medicine, University of Porto, 200-319 Porto, Portugal
3Instituto de Biologia e Molecular e Celular (IBMC), University of Porto, 4150-180 Porto, Portugal
4Institute of Histology and Embryology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal

Received 1 March 2011; Accepted 28 March 2011

Academic Editor: Ervin Kocjancic

Copyright © 2011 Tiago Antunes-Lopes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. E. Irwin, I. Milsom, S. Hunskaar et al., “Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study,” European Urology, vol. 50, no. 6, pp. 1306–1315, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. P. Abrams, L. Cardozo, M. Fall et al., “The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society,” Neurourology and Urodynamics, vol. 21, no. 2, pp. 167–178, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. C. R. Chapple, W. Artibani, L. D. Cardozo et al., “The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects,” British Journal of Urology International, vol. 95, no. 3, pp. 335–340, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. Nixon, S. Colman, L. Sabounjian et al., “A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials,” Journal of Urology, vol. 174, no. 2, pp. 604–607, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. J. S. Starkman and R. R. Dmochowski, “Urgency assessment in the evaluation of overactive bladder (OAB),” Neurourology and Urodynamics, vol. 27, no. 1, pp. 13–21, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. H. Hashim and P. Abrams, “Is the bladder a reliable witness for predicting detrusor overactivity?” Journal of Urology, vol. 175, no. 1, pp. 191–195, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. H. T. Liu, M. B. Chancellor, and H. C. Kuo, “Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder,” British Journal of Urology International, vol. 103, no. 12, pp. 1668–1672, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. H. C. Kuo, “Measurement of detrusor wall thickness in women with overactive bladder by transvaginal and transabdominal sonography,” International Urogynecology Journal and Pelvic Floor Dysfunction, vol. 20, no. 11, pp. 1293–1299, 2009. View at Google Scholar · View at Scopus
  9. F. Cruz, J. Heesakkers, V. Khullar, and A. Tubaro, “Bladder wall thickness in overactive bladder: does it have a role?” European Urology, vol. 8, no. 9, supplement, pp. 769–771, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Oelke, K. Höfner, U. Jonas, J. J. de la Rosette, D. T. Ubbink, and H. Wijkstra, “Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume,” European Urology, vol. 52, no. 3, pp. 827–835, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. T. M. Kessler, R. Gerber, F. C. Burkhard, U. E. Studer, and H. Danuser, “Ultrasound assessment of detrusor thickness in men-can it predict bladder outlet obstruction and replace pressure flow study?” Journal of Urology, vol. 175, no. 6, pp. 2170–2173, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. F. F. Farag, F. M. Martens, K. W. D'Hauwers, W. F. Feitz, and J. P. Heesakkers, “Near-infrared spectroscopy: a novel, noninvasive, diagnostic method for detrusor overactivity in patients with overactive bladder symptoms—a preliminary and experimental study,” European Urology, vol. 59, no. 5, pp. 757–762, 2011. View at Publisher · View at Google Scholar · View at PubMed
  13. S. J. Allen and D. Dawbarn, “Clinical relevance of the neurotrophins and their receptors,” Clinical Science, vol. 110, no. 2, pp. 175–191, 2006. View at Publisher · View at Google Scholar · View at PubMed
  14. W. D. Steers and J. B. Tuttle, “Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders,” Nature Clinical Practice Urology, vol. 3, no. 2, pp. 101–110, 2006. View at Publisher · View at Google Scholar · View at PubMed
  15. L. A. Birder and W. C. de Groat, “Mechanisms of disease: involvement of the urothelium in bladder dysfunction,” Nature Clinical Practice Urology, vol. 4, no. 1, pp. 46–54, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. R. Levi-Montalcini, “Nerve growth factor,” Science, vol. 187, no. 4172, p. 113, 1975. View at Google Scholar
  17. S. Pezet and S. B. McMahon, “Neurotrophins: mediators and modulators of pain,” Annual Review of Neuroscience, vol. 29, pp. 507–538, 2006. View at Publisher · View at Google Scholar · View at PubMed
  18. D. H. Bennett, M. Koltzenburg, J. V. Priestley, D. L. Shelton, and S. B. McMahon, “Endogenous nerve growth factor regulates the sensitivity of nociceptors in the adult rat,” European Journal of Neuroscience, vol. 10, no. 4, pp. 1282–1291, 1998. View at Publisher · View at Google Scholar
  19. N. Dmitrieva, D. Shelton, A. S. C. Rice, and S. B. McMahon, “The role of nerve growth factor in a model of visceral inflammation,” Neuroscience, vol. 78, no. 2, pp. 449–459, 1997. View at Publisher · View at Google Scholar
  20. S. I. Jaggar, H. C. F. Scott, and A. S. C. Rice, “Inflammation of the rat urinary bladder is associated with a referred thermal hyperalgesia which is nerve growth factor dependent,” British Journal of Anaesthesia, vol. 83, no. 3, pp. 442–448, 1999. View at Google Scholar
  21. H. C. Kuo, “Recent investigations of urinary nerve growth factor as a biomarker for overactive bladder syndrome,” Korean Journal of Urology, vol. 50, no. 9, pp. 831–835, 2009. View at Publisher · View at Google Scholar
  22. Y. C. Chuang, M. O. Fraser, Y. Yu, M. B. Chancellor, W. C. De Groat, and N. Yoshimura, “The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor,” Journal of Urology, vol. 165, no. 3, pp. 975–979, 2001. View at Google Scholar
  23. N. Yoshimura, N. E. Bennett, Y. Hayashi et al., “Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats,” Journal of Neuroscience, vol. 26, no. 42, pp. 10847–10855, 2006. View at Publisher · View at Google Scholar · View at PubMed
  24. K. Lamb, G. F. Gebhart, and K. Bielefeldt, “Increased nerve growth factor expression triggers bladder overactivity,” Journal of Pain, vol. 5, no. 3, pp. 150–156, 2004. View at Publisher · View at Google Scholar
  25. P. Zvara and M. A. Vizzard, “Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord,” BMC Physiology, vol. 7, pp. 9–19, 2007. View at Publisher · View at Google Scholar · View at PubMed
  26. B. Frias, A. Charrua, R. Pinto et al., “Intrathecal blockade of Trk receptor and neurotrophins sequestration reduces pain and urinary frequency in an animal model of chronic bladder inflammation,” Neurourology and Urodynamics, vol. 28, no. 7, pp. 708–708, 2009. View at Google Scholar
  27. S. Seki, K. Sasaki, M. O. Fraser et al., “Immunoneutralization of nerve growth factor in the lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats,” Journal of Urology, vol. 168, no. 5, pp. 2269–2274, 2002. View at Google Scholar
  28. S. Seki, K. Sasaki, Y. Igawa et al., “Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats,” Journal of Urology, vol. 171, no. 1, pp. 478–482, 2004. View at Publisher · View at Google Scholar · View at PubMed
  29. F. Cruz et al., “NGF-induced detrusor overactivity is TRPV1 dependent,” European Urology Supplements, vol. 9, no. 2, p. 69, 2010. View at Google Scholar
  30. J. B. Tuttle, W. D. Steers, M. Albo, and E. Nataluk, “Neural input regulates tissue NGF and growth of the adult rat urinary bladder,” Journal of the Autonomic Nervous System, vol. 49, no. 2, pp. 147–158, 1994. View at Publisher · View at Google Scholar
  31. E. M. Lowe, P. Anand, G. Terenghi, R. E. Williams-Chestnut, D. V. Sinicropi, and J. L. Osborne, “Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis,” British Journal of Urology, vol. 79, no. 4, pp. 572–577, 1997. View at Google Scholar
  32. M. C. Dupont, J. M. Spitsbergen, K. B. Kim, J. B. Tuttle, and W. D. Steers, “Histological and neurotrophic changes triggered by varying models of bladder inflammation,” Journal of Urology, vol. 166, no. 3, pp. 1111–1118, 2001. View at Google Scholar
  33. M. A. Vizzard et al., “Neurochemical plasticity and the role of neurotrophic factors in bladder reflex pathways after spinal cord injury,” Progress in Brain Research, vol. 152, pp. 97–115, 2006. View at Publisher · View at Google Scholar · View at PubMed
  34. H. T. Liu, A. B. Liu, M. B. Chancellor, and H. C. Kuo, “Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident,” British Journal of Urology International, vol. 104, no. 8, pp. 1158–1162, 2009. View at Publisher · View at Google Scholar · View at PubMed
  35. R. Pinto, T. Lopes, B. Frias et al., “Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis,” European Urology, vol. 58, no. 3, pp. 360–365, 2010. View at Publisher · View at Google Scholar · View at PubMed
  36. W. D. Steers, S. Kolbeck, D. Creedon, and J. B. Tuttle, “Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function,” Journal of Clinical Investigation, vol. 88, no. 5, pp. 1709–1715, 1991. View at Google Scholar
  37. J. C. Kim, E. Y. Park, S. I. Seo, Y. H. Park, and T. K. Hwang, “Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder,” Journal of Urology, vol. 175, no. 5, pp. 1773–1776, 2006. View at Publisher · View at Google Scholar · View at PubMed
  38. T. Yokoyama, H. Kumon, and A. Nagai, “Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder,” Neurourology and Urodynamics, vol. 27, no. 5, pp. 417–420, 2008. View at Publisher · View at Google Scholar · View at PubMed
  39. H. T. Liu and H. C. Kuo, “Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder,” Journal of Urology, vol. 179, no. 6, pp. 2270–2274, 2008. View at Publisher · View at Google Scholar · View at PubMed
  40. H. T. Liu, C. Y. Chen, and H. C. Kuo, “Urinary nerve growth factor in women with overactive bladder syndrome,” British Journal of Urology International, vol. 107, no. 5, pp. 799–803, 2011. View at Publisher · View at Google Scholar · View at PubMed
  41. C. Y. Chen and H. C. Kuo, “Novel urinary biomarkers in the diagnosis and assessment of overactive bladder,” Incontinence and Pelvic Floor Dysfunction, vol. 3, no. 1, pp. 20–23, 2009. View at Google Scholar
  42. T. Antunes-Lopes et al., “Urinary neurotrophins—potential biomarkers of overactive bladder,” Journal of Urology, vol. 185, no. 4S, pp. 780–781, 2011. View at Google Scholar
  43. L. A. Birder, A. Wolf-Johnston, D. Griffiths, and N. M. Resnick, “Role of urothelial nerve growth factor in human bladder function,” Neurourology and Urodynamics, vol. 26, no. 3, pp. 405–409, 2007. View at Publisher · View at Google Scholar · View at PubMed
  44. H. T. Liu and H. C. Kuo, “Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment,” Urology, vol. 72, no. 1, pp. 104–108, 2008. View at Publisher · View at Google Scholar · View at PubMed
  45. H. T. Liu, M. B. Chancellor, and H. C. Kuo, “Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder,” British Journal of Urology International, vol. 103, no. 12, pp. 1668–1672, 2009. View at Publisher · View at Google Scholar · View at PubMed
  46. H. T. Liu, M. B. Chancellor, and H. C. Kuo, “Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection,” European Urology, vol. 56, no. 4, pp. 700–707, 2009. View at Publisher · View at Google Scholar · View at PubMed
  47. S. Pezet, M. Malcangio, and S. B. McMahon, “BDNF: a neuromodulator in nociceptive pathways?” Brain Research Reviews, vol. 40, no. 1-3, pp. 240–249, 2002. View at Publisher · View at Google Scholar
  48. B. J. Kerr, E. J. Bradbury, D. L. H. Bennett et al., “Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord,” Journal of Neuroscience, vol. 19, no. 12, pp. 5138–5148, 1999. View at Google Scholar
  49. A. Merighi, C. Salio, A. Ghirri et al., “BDNF as a pain modulator,” Progress in Neurobiology, vol. 85, no. 3, pp. 297–317, 2008. View at Publisher · View at Google Scholar · View at PubMed
  50. G. J. Michael, S. Averill, A. Nitkunan et al., “Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord,” Journal of Neuroscience, vol. 17, no. 21, pp. 8476–8490, 1997. View at Google Scholar
  51. D. Hellard, T. Brosenitsch, B. Fritzsch, and D. M. Katz, “Cranial sensory neuron development in the absence of brain-derived neurotrophic factor in BDNF/Bax double null mice,” Developmental Biology, vol. 275, no. 1, pp. 34–43, 2004. View at Publisher · View at Google Scholar · View at PubMed
  52. K. Obata and K. Noguchi, “BDNF in sensory neurons and chronic pain,” Neuroscience Research, vol. 55, no. 1, pp. 1–10, 2006. View at Publisher · View at Google Scholar · View at PubMed
  53. X. F. Zhou and R. A. Rush, “Endogenous brain-derived neurotrophic factor is anterogradely transported in primary sensory neurons,” Neuroscience, vol. 74, no. 4, pp. 945–951, 1996. View at Publisher · View at Google Scholar
  54. J. Zhao, A. Seereeram, M. A. Nassar et al., “Nociceptor-derived brain-derived neurotrophic factor regulates acute and inflammatory but not neuropathic pain,” Molecular and Cellular Neuroscience, vol. 31, no. 3, pp. 539–548, 2006. View at Publisher · View at Google Scholar · View at PubMed
  55. A. Merighi, G. Carmignoto, S. Gobbo et al., “Neurotrophins in spinal cord nociceptive pathways,” Progress in Brain Research, vol. 146, pp. 291–321, 2004. View at Publisher · View at Google Scholar
  56. L. Y. Qiao and M. A. Vizzard, “Cystitis-induced upregulation of tyrosine kinase (TrkA, TrkB) receptor expression and phosphorylation in rat micturition pathways,” Journal of Comparative Neurology, vol. 454, no. 2, pp. 200–211, 2002. View at Publisher · View at Google Scholar · View at PubMed
  57. L. Qiao and M. A. Vizzard, “Up-regulation of tyrosine kinase (Trka, Trkb) receptor expression and phosphorylation in lumbosacral dorsal root ganglia after chronic spinal cord (T8-T10) injury,” Journal of Comparative Neurology, vol. 449, no. 3, pp. 217–230, 2002. View at Publisher · View at Google Scholar · View at PubMed
  58. L. Y. Qiao and M. A. Vizzard, “Spinal cord injury-induced expression of TrkA, TrkB, phosphorylated CREB, and c-Jun in rat lumbosacral dorsal root ganglia,” Journal of Comparative Neurology, vol. 482, no. 2, pp. 142–154, 2005. View at Publisher · View at Google Scholar · View at PubMed
  59. R. Pinto, B. Frias, S. Allen et al., “Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis,” Neuroscience, vol. 166, no. 3, pp. 907–916, 2010. View at Publisher · View at Google Scholar · View at PubMed
  60. T. Antunes-Lopes et al., “Urinary levels of brain derived neurotrophic factor (BDNF) in women with overactive bladder (OAB) syndrome correlate with the severity of symptoms,” European Urology Supplements, vol. 10, no. 2, pp. 277–278, 2011. View at Google Scholar
  61. H. T. Liu and H. C. Kuo, “Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention,” Neurourology and Urodynamics, vol. 28, no. 1, pp. 78–81, 2009. View at Publisher · View at Google Scholar · View at PubMed
  62. V. Y. Hu, P. Zvara, A. Dattilio et al., “Decrease in bladder overactivity with REN1820 in rats with cyclophosphamide induced cystitis,” Journal of Urology, vol. 173, no. 3, pp. 1016–1021, 2005. View at Publisher · View at Google Scholar · View at PubMed
  63. J. C. Kim, E. Y. Park, S. I. Seo, Y. H. Park, and T. K. Hwang, “Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder,” Journal of Urology, vol. 175, no. 5, pp. 1773–1776, 2006. View at Publisher · View at Google Scholar · View at PubMed
  64. O. Yokoyama, Y. Miwa, N. Oyama, Y. Aoki, H. Ito, and H. Akino, “Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure,” Journal of Urology, vol. 178, no. 5, pp. 2208–2212, 2007. View at Publisher · View at Google Scholar · View at PubMed
  65. X. Su, L. A. Leon, C. W. Wu et al., “Modulation of bladder function by prostaglandin EP3 receptors in the central nervous system,” American Journal of Physiology, vol. 295, no. 4, pp. F984–F994, 2008. View at Publisher · View at Google Scholar · View at PubMed
  66. H. T. Liu, P. Tyagi, M. B. Chancellor, and H. C. Kuo, “Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity,” British Journal of Urology International, vol. 106, no. 11, pp. 1681–1685, 2010. View at Publisher · View at Google Scholar · View at PubMed
  67. D. Wilbraham, T. Masuda, S. Deacon, R. Kuwayama, and S. Vincent, “Safety, tolerability, and pharmacokinetic of multiple ascending doses of the EP-1 receptor antagonist ONO-8539, a potential new and novel therapy to overactive bladder in healthy young and elderly subjects,” European Urology Supplements, vol. 9, no. 2, p. 250, 2010. View at Google Scholar
  68. P. Tyagi, D. Barclay, R. Zamora et al., “Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study,” International Urology and Nephrology, vol. 42, no. 3, pp. 629–635, 2010. View at Publisher · View at Google Scholar · View at PubMed
  69. E. Compérat, A. Reitz, A. Delcourt, F. Capron, P. Denys, and E. Chartier-Kastler, “Histologic features in the urinary bladder wall affected from neurogenic overactivity-a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A,” European Urology, vol. 50, no. 5, pp. 1058–1064, 2006. View at Publisher · View at Google Scholar · View at PubMed
  70. A. Apostolidis, T. S. Jacques, A. Freeman et al., “Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity,” European Urology, vol. 53, no. 6, pp. 1245–1253, 2008. View at Publisher · View at Google Scholar · View at PubMed
  71. Y. C. Chuang, V. Tyagi, R. T. Liu, and M. B. Chancellor, “Urine and serum C-reactive protein levels as potential biomarkers of lower urinary tract symptoms,” Urological Science, vol. 21, no. 3, pp. 132–136, 2010. View at Publisher · View at Google Scholar
  72. V. Kupelian, K. T. McVary, M. J. Barry et al., “Association of C-reactive protein (CPR) and lower urinary tract symptoms in men and women: results from boston area community health survey,” Urology, vol. 73, no. 5, pp. 950–957, 2009. View at Publisher · View at Google Scholar · View at PubMed